Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course

Cathelijne Fokkema, Madelon M.E. de Jong, Sabrin Tahri, Davine Hofste Op Bruinink, Zoltan Kellermayer, Chelsea den Hollander, Michael Vermeulen, Natalie Papazian, Mark van Duin, Remco Hoogenboezem, Michiel J.W. Wevers, Vincent H.J. van der Velden, Mathijs A. Sanders, Annemiek Broijl, Pieter Sonneveld, Tom Cupedo

Blood (2022) 140 (Supplement 1): 9917–9918.

https://doi.org/10.1182/blood-2022-166162

Published: 2022

Journal Articles

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Blood (2022) 140 (Supplement 1): 1566–1567.

https://doi.org/10.1182/blood-2022-170249

Published: 2022

Journal Articles

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Davine Hofste op Bruinink, MD MSc, Mark van Duin, PhD, Meral Beksac, MD, Christoph Driessen, MD, Heinz Ludwig, MD, Michael Vermeulen, BSc, Rowan Kuiper, MSc, Martin H van Vliet, PhD, Bronno van der Holt, PhD, Roman Hajek, MD PhD, Hans Erik Johnsen, MD Professor, Meletios A Dimopoulos, MD, Antonio Palumbo, MD, Michele Cavo, MD, Pieter Sonneveld, MD PhD

Blood (2018) 132 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2018-99-119873

Published: 2018

Journal Articles

Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse

Kristine Misund, PhD, Davine Hofste Op Bruinink, MD, Eivind Coward, PhD, Remco Hoogenboezem, MSc, Even H Rustad, MD, Eivind Hovig, PhD, Anders Sundan, PhD, Ola Myklebost, PhD, Pieter Sonneveld, MD PhD, Anders Waage, MD PhD

Blood (2018) 132 (Supplement 1): 3157.

https://doi.org/10.1182/blood-2018-99-113553

Published: 2018

Journal Articles

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Davine Hofste Op Bruinink, MD, Vincent van der Velden, PhD, Mark van Duin, PhD, Berna Beverloo, PhD, Jeroen te Marvelde, BSc, Chelsea den Hollander, BSc, Rowan Kuiper, MSc, Michel Delforge, MDPhD, Martin H van Vliet, PhD, Niels WCJ van de Donk, MDPhD, Hervé Avet-Loiseau, MDPhD, Philippe Moreau, MDPhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 4368.

https://doi.org/10.1182/blood.V130.Suppl_1.4368.4368

Published: 2017

Journal Articles

Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity

Davine Hofste op Bruinink, MD MSc, Stefania Oliva, MD, Lucie Rihova, PhD, Bronno van der Holt, PhD, Milena Gilestro, BSc, Jeroen G. te Marvelde, BSc, Pavla Vsianska, MSc, Alexander Schmitz, PhD, Helle Høholt, BSc, Hans Erik Johnsen, MDDMSc, Mario Boccadoro, MD, Roman Hajek, MD, Pieter Sonneveld, MD PhD, Antonio Palumbo, MD, Paola Omedè, PhD, Vincent H.J. van der Velden, PhD

Blood (2016) 128 (22): 2072.

https://doi.org/10.1182/blood.V128.22.2072.2072

Published: 2016

Journal Articles

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Blood (2016) 128 (22): 3271.

https://doi.org/10.1182/blood.V128.22.3271.3271

Published: 2016

Journal Articles

Targeted Genomic Mutation Panel (M 3 P) Results from 504 Multiple Myeloma (MM) Patients

Blood (2015) 126 (23): 1795.

https://doi.org/10.1182/blood.V126.23.1795.1795

Published: 2015

Journal Articles

M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma

Davine Hofste op Bruinink, MD MSc, K. Martin Kortüm, MD, Mark van Duin, PhD, Mathijs A. Sanders, PhD, Remco Hoogenboezem, MSc, Michael Vermeulen, BSc, Laura Bruins, Jonathan Ahmann, Annemiek Broijl, MD PhD, Sonja Zweegman, MD PhD, Esteban Braggio, PhD, Bronno van der Holt, PhD, A. Keith Stewart, MD PhD, Pieter Sonneveld, MD PhD

Blood (2015) 126 (23): 2984.

https://doi.org/10.1182/blood.V126.23.2984.2984

Published: 2015

NARROW

MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Targeted Genomic Mutation Panel (M 3 P) Results from 504 Multiple Myeloma (MM) Patients

M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only